Completed Research Studies

We would like to thank the patients at the Penn Vasculitis Center for their participation in our research studies. Your contribution has made a lasting impact on the field and will advance the care of future patients.

Please click on a disease in the drop down list to view brief summaries and results of selected studies that the Penn Vasculitis Center has conducted over the years. All studies on this page are closed to enrollment.

For more detailed information about these studies, click on the NCT #.

  • Safety and Efficacy of Two Different Dose Regimens of IFX-1 as Add-On to Standard of Care in Subjects with GPA and MPA: IXPLORE

    Study Findings: The study drug, vilobelimab, was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of care.

    ClinicalTrials.gov ID: NCT03712345

    Study Dates: 2018-2021

    Disease(s): Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)

  • Phase 3 Study of Avacopan for the Treatment of ANCA-Associated Vasculitis: ADVOCATE

    Study Findings: Patients who received avacopan were more likely to stay in remission versus those who were only taking prednisone. View Publication.

    ClinicalTrials.gov ID: NCT02994927

    Study Dates: 2017-2020

    Disease(s): Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)

  • Phase 2 Study of Avacopan for the Treatment of ANCA-Associated Vasculitis: CLASSIC

    Study Findings: This study demonstrated that avacopan was well tolerated in patients with AAV when added to current standard of care treatment.  This study led to a Phase 3 study called ADVOCATE. View Publication.

    ClinicalTrials.gov ID: NCT02222155

    Study Dates: 2014-2018

    Disease(s): Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)

  • Mepolizumab Compared with Placebo in Subjects with EGPA Receiving Standard of Care Therapy: MIRRA

    Study Findings: This was the first clinical trial exclusively performed in patients with EGPA. Compared to prednisone alone, patients with EGPA receiving mepolizumab had more weeks in remission and were able to taper prednisone to lower doses. View Publication.

    ClinicalTrials.gov ID: NCT02020889

    Study Dates: 2014-2017

    Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA)

  • Tocilizumab in Subjects with Giant Cell Arteritis: GiACTA

    Study Findings: This study showed that weekly tocilizumab (Actemra®) treatment, initially in combination with a 6-month steroid taper, enabled significantly more patients with GCA to achieve sustained remission while also reducing steroid exposure compared with taking steroids alone. View Publication.

    ClinicalTrials.gov ID: NCT01791153

    Study Dates: 2013-2018

    Disease(s): Giant Cell Arteritis (GCA)

  • The Diagnostic and Classification Criteria for Vasculitis Study: DCVAS

    Study Findings: This was an observational study designed to develop and validate diagnostic criteria and to improve and validate classification criteria for primary systemic vasculitis. The updated classification criteria are intended to improve the quality of future clinical trials and clinical research because patients with specific diseases will be able to be reliably grouped for studies.

    ClinicalTrials.gov ID: NCT01066208

    Study Dates: 2013-2018

    Disease(s): Other

  • Rituximab Compared with Azathioprine as Maintenance Therapy in Relapsing ANCA-Associated Vasculitis: RITAZAREM

    Study Findings: This study demonstrated that patients with ANCA-associated vasculitis, with a prior history of relapse, who receive maintenance therapy with rituximab are more likely to remain in remission than those given azathioprine. View Publication.

    ClinicalTrials.gov ID: NCT01697267

    Study Dates: 2012-2020

    Disease(s): Granulomatosis with Polyangiitis (GPA)

  • Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis: PEXIVAS

    Study Findings: This was the largest international clinical trial performed in AAV (GPA and MPA). The study found that the use of plasma exchange does not improve survival or risk of end-stage renal disease. Compared to standard doses of prednisone, a more rapid taper of prednisone is just as effective and safer (fewer serious infections) than plasma exchange. View Publication.

    ClinicalTrials.gov ID: NCT00987389

    Study Dates: 2012-2019

    Disease(s): Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)

  • Long-Term Safety Study of Rituximab in Subjects with GPA and MPA

    Study Findings: The study demonstrated that the safety profile of long-term treatment (up to 4 years) with rituximab was consistent with that of rituximab administered for shorter durations. View Publication.

    ClinicalTrials.gov ID: NCT01613599

    Study Dates: 2012-2017

    Disease(s): Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)

  • Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis: ABROGATE

    Study Findings: Study results are pending.

    ClinicalTrials.gov ID: NCT02108860

    Study Dates: 2015-2023

    Disease(s): Granulomatosis with Polyangiitis (GPA)

  • Upadacitinib in Subjects with Giant Cell Arteritis: SELECT-GCA

    Study Findings:  This study showed that patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®) with a steroid taper regimen were more likely to achieve sustained remission compared to patients receiving placebo with a steroid taper regimen. View publication

    ClinicalTrials.gov ID NCT03725202

    Study Dates: 2019-2023

    Disease(s): Giant Cell Arteritis (GCA)

  • Benralizumab Compared to Mepolizumab in Subjects with EGPA Receiving Standard of Care Therapy: MANDARA

    Study Findings: Benralizumab (Fasenra®) and mepolizumab (Nucala®) were similarly effective at inducing remission in EGPA.  It also showed that eliminating oral glucocorticoids in EGPA treatment is now achievable using eosinophil-focused therapies, though further research is necessary. View Publication.

    ClinicalTrials.gov: NCT04157348

    Study Dates: 2020-2023

    Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA)